Published in Cancer Res on September 19, 2017
Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol (2010) 6.04
Oncology meets immunology: the cancer-immunity cycle. Immunity (2013) 5.60
Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37
The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol (2012) 3.97
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol (2013) 3.74
Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol (2015) 3.57
Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol (2012) 3.43
Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science (2013) 3.25
Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell (2013) 2.89
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res (2013) 2.76
Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood (2000) 2.64
Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol (2015) 2.32
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature (2012) 2.08
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy. Immunol Cell Biol (2014) 2.02
CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res (2014) 2.00
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med (2013) 1.96
Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest (2012) 1.92
Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. Nature (2015) 1.87
Neutrophils mediate antibody-induced antitumor effects in mice. Blood (2013) 1.66
Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res (2013) 1.63
Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res (2011) 1.62
Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci Transl Med (2015) 1.58
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood (2013) 1.55
Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54
Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med (2016) 1.52
Innate immune recognition of cancer. Annu Rev Immunol (2015) 1.52
Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses. Cancer Cell (2016) 1.46
Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother (2010) 1.42
Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest (2014) 1.33
Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest (2014) 1.29
Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol (2011) 1.24
Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response. Immunity (2015) 1.22
Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology (2013) 1.21
Dendritic cells and cancer immunotherapy. Curr Opin Immunol (2014) 1.11
Macrophages are critical effectors of antibody therapies for cancer. MAbs (2015) 1.09
Driving CAR T-cells forward. Nat Rev Clin Oncol (2016) 1.09
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. Semin Oncol (2015) 1.06
Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models. Leuk Lymphoma (2010) 1.04
Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. Cancer Cell (2015) 1.04
Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J Immunol (2014) 1.03
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell (2017) 0.94
The role of myeloid cells in cancer therapies. Nat Rev Cancer (2016) 0.92
Clinical applications of gamma delta T cells with multivalent immunity. Front Immunol (2014) 0.89
A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. Cancer Immunol Res (2014) 0.87
Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade. Cancer Immunol Res (2016) 0.82
Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19. Front Immunol (2016) 0.80
An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. Clin Cancer Res (2016) 0.80
Emerging Roles for Eosinophils in the Tumor Microenvironment. Trends Cancer (2016) 0.76
A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice. Cancer Immunol Res (2017) 0.76
Temporally Programmed CD8α(+) DC Activation Enhances Combination Cancer Immunotherapy. Cell Rep (2016) 0.75